These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Vascular protectants for the treatment of atherosclerosis. Tardif JC; Grégoire J; Lavoie MA; L'Allier PL Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):385-92. PubMed ID: 15030266 [TBL] [Abstract][Full Text] [Related]
11. Prevention of restenosis with antioxidants: mechanisms and implications. Tardif JC; Grégoire J; L'Allier PL Am J Cardiovasc Drugs; 2002; 2(5):323-34. PubMed ID: 14727962 [TBL] [Abstract][Full Text] [Related]
12. Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Preiss DJ; Sattar N Int J Clin Pract; 2007 Apr; 61(4):697-701. PubMed ID: 17394445 [TBL] [Abstract][Full Text] [Related]
13. AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel antioxidant and anti-inflammatory compound: cellular and biochemical characterization of antioxidant activity and inhibition of redox-sensitive inflammatory gene expression. Kunsch C; Luchoomun J; Chen XL; Dodd GL; Karu KS; Meng CQ; Marino EM; Olliff LK; Piper JD; Qiu FH; Sikorski JA; Somers PK; Suen KL; Thomas S; Whalen AM; Wasserman MA; Sundell CL J Pharmacol Exp Ther; 2005 May; 313(2):492-501. PubMed ID: 15701708 [TBL] [Abstract][Full Text] [Related]
14. Antioxidants: the good, the bad and the ugly. Tardif JC Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):61B-65B. PubMed ID: 16498514 [TBL] [Abstract][Full Text] [Related]
15. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Meng CQ; Somers PK; Rachita CL; Holt LA; Hoong LK; Zheng XS; Simpson JE; Hill RR; Olliff LK; Kunsch C; Sundell CL; Parthasarathy S; Saxena U; Sikorski JA; Wasserman MA Bioorg Med Chem Lett; 2002 Sep; 12(18):2545-8. PubMed ID: 12182856 [TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of anti-atherogenic action of probucol]. Ohya T; Egusa G Nihon Rinsho; 1999 Dec; 57(12):2831-6. PubMed ID: 10638221 [TBL] [Abstract][Full Text] [Related]
17. The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease. Serebruany V; Malinin A; Scott R J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):191-6. PubMed ID: 17056832 [TBL] [Abstract][Full Text] [Related]
18. N,N'-diacetyl-L-cystine (DiNAC), the disulphide dimer of N-acetylcysteine, inhibits atherosclerosis in WHHL rabbits: evidence for immunomodulatory agents as a new approach to prevent atherosclerosis. Wågberg M; Jansson AH; Westerlund C; Ostlund-Lindqvist AM; Särnstrand B; Bergstrand H; Pettersson K J Pharmacol Exp Ther; 2001 Oct; 299(1):76-82. PubMed ID: 11561065 [TBL] [Abstract][Full Text] [Related]
19. Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects. Muldrew KM; Franks AM Expert Opin Investig Drugs; 2009 Apr; 18(4):531-9. PubMed ID: 19335281 [TBL] [Abstract][Full Text] [Related]